CA2379532A1 - Isoformes de molecules de snare et leurs utilisations pour moduler l'exocytose cellulaire - Google Patents

Isoformes de molecules de snare et leurs utilisations pour moduler l'exocytose cellulaire Download PDF

Info

Publication number
CA2379532A1
CA2379532A1 CA002379532A CA2379532A CA2379532A1 CA 2379532 A1 CA2379532 A1 CA 2379532A1 CA 002379532 A CA002379532 A CA 002379532A CA 2379532 A CA2379532 A CA 2379532A CA 2379532 A1 CA2379532 A1 CA 2379532A1
Authority
CA
Canada
Prior art keywords
snare
toxin
snap
bont
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002379532A
Other languages
English (en)
Inventor
James Oliver Dolly
Gregory A. 0'sullivan
Nadiem Mohammed
Patrick G. Foran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2379532A1 publication Critical patent/CA2379532A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procédé servant à traiter un patient souffrant d'empoisonnement par une toxine de Clostridium, ce qui consiste à introduire dans une cellule de ce patient un SNARE (récepteur de protéine de fixation-de protéine de fusion sensible à N-éthylmaléinide) résistant à la protéolyse par ladite toxine de Clostridium (SNARE résistant à la toxine) et/ou capable d'inhiber la toxine de Clostridium. SNARE résistant à la protéolyse peut être un polypeptide associé à un synaptosome de 25 kDA (SNAP-25). SNAP-25 est, de préférence, résistant à la protéolyse par BoNT/A, BoNT/E et BoNT/C. Procédé de traitement de traitement d'un patient nécessitant l'inhibition d'une exocytose dépendant de SNARE depuis une cellule capable d'effectuer l'exocytose dépendante de SNARE, ce qui consiste à introduire dans ladite cellule du patient un dérivé (SNARE inhibiteur) capable d'inhiber l'exocytose dépendante de SNARE. Ce SNARE inhibiteur peut être un fragment de SNAP-25 pouvant être obtenu par clivage de SNAP-25 par la toxine A de Botulinum (BoNT/A). Cette cellule peut être, par exemple, une cellule nerveuse, une cellule adréno-chromaffine ou une cellule sécrétant de l'insuline. On peut introduire SNARE dans la cellule par expression d'un produit de recombinaison de polynucléotide. SNARE ou ce produit de recombinaison peuvent être ciblés vers une cellule nerveuse au moyen d'une neurotoxine inactive de Clostridium. SNARE peut être exprimé sous le contrôle direct ou indirect d'un promoteur spécifique pour la cellule ciblée.
CA002379532A 1999-08-20 2000-08-18 Isoformes de molecules de snare et leurs utilisations pour moduler l'exocytose cellulaire Abandoned CA2379532A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14999399P 1999-08-20 1999-08-20
US60/149,993 1999-08-20
PCT/GB2000/003196 WO2001018038A2 (fr) 1999-08-20 2000-08-18 Isoformes de molecules de snare et leurs utilisations pour moduler l'exocytose cellulaire

Publications (1)

Publication Number Publication Date
CA2379532A1 true CA2379532A1 (fr) 2001-03-15

Family

ID=22532674

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002379532A Abandoned CA2379532A1 (fr) 1999-08-20 2000-08-18 Isoformes de molecules de snare et leurs utilisations pour moduler l'exocytose cellulaire

Country Status (5)

Country Link
EP (1) EP1210444A2 (fr)
JP (1) JP2003508092A (fr)
AU (1) AU781226B2 (fr)
CA (1) CA2379532A1 (fr)
WO (1) WO2001018038A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
GB0111146D0 (en) * 2001-05-04 2001-06-27 Imp College Innovations Ltd Methods
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US20060153876A1 (en) 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
CA2588758C (fr) 2004-11-22 2017-01-03 New York University Genes clostridiaux genetiquement modifies, proteines codees par ces genes modifies et utilisations de ceux-ci
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
EP2649985A1 (fr) * 2012-04-13 2013-10-16 Lipotec, S.A. Composés inhibant l'exocytosis neuronale (III)
MX356343B (es) * 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compuestos que inhiben la exocitosis neuronal (ii).
US9315549B2 (en) 2013-01-28 2016-04-19 New York University Treatment methods using atoxic neurotoxin derivatives
EP3230457B1 (fr) 2014-12-09 2021-06-30 New York University Protéines de fusion de neurotoxine clostridienne, fusions de propeptides, leur expression et leur utilisation
KR102274841B1 (ko) * 2019-10-16 2021-07-12 주식회사 하울바이오 Snare 복합체를 억제하는 항-snap 25 항체 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138740T3 (es) * 1994-05-31 2000-01-16 Allergan Inc Modificacion de toxinas de clostridium utilizadas como proteinas de transporte.

Also Published As

Publication number Publication date
AU781226B2 (en) 2005-05-12
EP1210444A2 (fr) 2002-06-05
AU6852600A (en) 2001-04-10
JP2003508092A (ja) 2003-03-04
WO2001018038A2 (fr) 2001-03-15
WO2001018038A3 (fr) 2001-10-11

Similar Documents

Publication Publication Date Title
JP6496386B2 (ja) クロストリジウム・ヒストリチクム（ｃｌｏｓｔｒｉｄｉｕｍ ｈｉｓｔｏｌｙｔｉｃｕｍ）酵素およびその使用のための方法
AU781226B2 (en) Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis
JP5833039B2 (ja) 神経細胞に化合物を導入するために用いられる輸送タンパク質
Gaisano et al. Tetanus toxin light chain cleaves a vesicle-associated membrane protein (VAMP) isoform 2 in rat pancreatic zymogen granules and inhibits enzyme secretion.
Hayashi et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.
Brin Botulinum toxin: chemistry, pharmacology, toxicity, and immunology
AU2012334080B2 (en) Neurotoxins exhibiting shortened biological activity
Poulain et al. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action
KR101942106B1 (ko) 분해가능한 클로스트리듐 독소
Masuyer et al. Engineered botulinum neurotoxins as new therapeutics
ES2749049T3 (es) Fabricación de neurotoxinas recombinantes de Clostridium botulinum
JP3523879B2 (ja) 輸送タンパク質用クロストリジウム属細菌毒素の修飾
US6169074B1 (en) Peptide inhibitors of neurotransmitter secretion by neuronal cells
MX2011013014A (es) Neurotoxinas que exhiben actividad biologica acortada.
US20080107673A1 (en) Mutants of clostridium difficile toxin B and methods of use
JP2009513118A (ja) ボツリヌス神経毒ａタンパク質受容体およびその使用
TW201839133A (zh) 製造經蛋白分解處理之多肽之方法
JP2021506899A (ja) ボツリヌス毒素細胞結合ドメインポリペプチドおよび線維症関連障害の処置のための使用方法
CA2483658A1 (fr) Bont/e ou snap-25e utilises pour traiter une intoxication a la toxine botulique a ou c1 et inhiber la contraction musculaire
CA1341048C (fr) Methode et compositions pour la production de facteurs stimulateurs de l'adenylate cyclase (fsac) et de leurs antagonistes
Bohnert et al. Uptake and transport of clostridium neurotoxins
Simpson et al. The role of exoproteases in governing intraneuronal metabolism of botulinum toxin
DUPONT et al. Emmanuel lovER", Fréderig DoussAU", Etienne LoNCHAMP", Laetitia woLAND", Jean
Neale et al. Clostridial neurotoxins and membrane traffic at the synaptic terminal
WO2003080662A1 (fr) Modulateurs de proteine kinase c, sequences d'acides amines et nucleotidiques et utilisations de ceux-ci

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead